[HTML][HTML] The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

AK Shiau, D Barstad, PM Loria, L Cheng, PJ Kushner… - Cell, 1998 - cell.com
AK Shiau, D Barstad, PM Loria, L Cheng, PJ Kushner, DA Agard, GL Greene
Cell, 1998cell.com
Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by
interactions with coactivators. Receptor agonists promote coactivator binding, and
antagonists block coactivator binding. Here we report the crystal structure of the human
estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist
diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator
GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4 …
Abstract
Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators. Receptor agonists promote coactivator binding, and antagonists block coactivator binding. Here we report the crystal structure of the human estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT). In the DES-LBD-peptide complex, the peptide binds as a short α helix to a hydrophobic groove on the surface of the LBD. In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD. These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.
cell.com